Cargando…
Association between daily glucose fluctuation and coronary plaque properties in patients receiving adequate lipid-lowering therapy assessed by continuous glucose monitoring and optical coherence tomography
BACKGROUND: Glucose fluctuation has been recognized as a residual risk apart from dyslipidemia for the development of coronary artery disease (CAD). This study aimed to investigate the association between glucose fluctuation and coronary plaque morphology in CAD patients. METHODS: This prospective s...
Autores principales: | Kuroda, Masaru, Shinke, Toshiro, Sakaguchi, Kazuhiko, Otake, Hiromasa, Takaya, Tomofumi, Hirota, Yushi, Osue, Tsuyoshi, Kinutani, Hiroto, Konishi, Akihide, Takahashi, Hachidai, Terashita, Daisuke, Uzu, Kenzo, Hirata, Ken-ichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480895/ https://www.ncbi.nlm.nih.gov/pubmed/26062762 http://dx.doi.org/10.1186/s12933-015-0236-x |
Ejemplares similares
-
Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography
por: Kuroda, Masaru, et al.
Publicado: (2016) -
High perfusion pressure as a predictor of reperfusion pulmonary injury after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Kinutani, Hiroto, et al.
Publicado: (2015) -
The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE—A multicenter randomized controlled trial
por: Yamamoto, Hiroyuki, et al.
Publicado: (2021) -
Data on impact of monocytes and glucose fluctuation on plaque vulnerability in patients with coronary artery disease
por: Yamamoto, Hiroyuki, et al.
Publicado: (2018) -
Impact of daily glucose fluctuations on cardiovascular outcomes after percutaneous coronary intervention for patients with stable coronary artery disease undergoing lipid‐lowering therapy
por: Yamamoto, Hiroyuki, et al.
Publicado: (2020)